Treatment of muscle-invasive bladder cancer: Progress and new challenges

Expert Review of Anticancer Therapy

Volumn 4, Issue 6, 2004, Pages 1047-1056

  Herring, Judi C ^a   Kamat, Ashish M ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjuvant; Bladder cancer; Chemotherapy; Cystectomy; Neoadjuvant

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FOLINIC ACID; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; VINBLASTINE;

ALOPECIA; ANEMIA; BLADDER CANCER; BLADDER MUSCLE; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYSTECTOMY; DIAGNOSTIC IMAGING; DIARRHEA; DRUG COST; FEVER; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; LYMPHADENECTOMY; METASTASIS; MUCOSA INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 10644286616     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.6.1047     Document Type: Review

References (62)

1. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001).
2. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol. 166, 490-493 (2001).
3. Pagano F, Bassi P, Galetti TP et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes, and metastases classification. J. Urol. 145, 45-50 (1991).
4. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vögeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol. 170, 433-437 (2003).
5. May M, Nitzke T, Helke C, Vogler H, Hoschke B. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium of the bladder. Scand. J. Urol. Nephrol. 38, 231-235 (2004).
6. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol. 163, 1693-1696 (2000).
7. Kim JK, Park SY, Ahn HJ, Kim CS, Cho KS. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 231(3), 725-731 (2004).
8. Braendengen M, Winderen M, Fossa SD. Clinical significance of routine precystectomy bone scans in patients with muscle-invasive bladder cancer. Br. J. Urol. 77(1), 36-40 (1996).
9. Hain SF, Maisey MN. Positron emission tomography for urological tumours. BJU Int. 92(2), 159-164 (2003).
10. 18F]-2-deoxy-D-glucose. Eur. Urol. 36(6), 582-587 (1999).
11. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19(20), 4005-4013 (2001).
12. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J. Clin. Oncol. 16(4), 1298-1301 (1998).
13. Amin MB, Ro JY, el-Sharkawy T et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am. J. Surg. Pathol. 18(12), 1224-1232 (1994).
14. Lopez-Beltran A, Pacelli A, Rothenberg HJ et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J. Urol. 159(5), 1497-1503 (1998).
15. Siefker-Radtke AO, Dinney CP, Abrahams NA et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience. J. Urol. 172(2), 481-484 (2004).
16. Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J. Urol 161(5), 1494-1497 (1999).
17. Abdel-Latif M, Abol-Enein H, El-Baz M et al. Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J. Urol. 172(1), 85-89 (2004).
18. Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J. Urol. 169(3), 955-960 (2003).
19. Millikan R, Siefker-Radtke A, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol, Oncol. 21(6), 464-467 (2003).
20. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today - a homogenous series without neoadjuvant therapy. J. Clin. Oncol. 21(4), 690-696 (2003).
21. Martinez-Pineiro JA, Gonzalez MM, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized Phase III study. J. Urol. 153(3 Pt 2), 964-973 (1995).
22. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J. Urol. 67(6), 608-615 (1991).
23. Coppin CM, Gospodarowicz MK, James K et al Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14(11), 2901-2907 (1996).
24. Bassi P, Pagano F, Pappagallo G et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: the GUONE multicenter Phase III trial. Eur. Urol. 33(Suppl.), 142 (1997) (Abstract 567).
25. Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 41(5), 447-456 (2002 ).
26. Abol-Enein H, El-Mekresh M, El-Baz M et al. Neoadjuvant chemotherapy in treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Br. J. Urol. 80(Suppl. 2 , 49 (1997) (Abstract 191).
27. Malmstrom P-U, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1.J. Urol. 155(6), 1903-1906 (1996).
28. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin - methotrexate chemotherapy for invasive bladder cancer. Scand. J. Urol. Nephrol. 36, 419-425 (2002).
29. Grossman HB, Natale R, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
30. Barjorin D. Plenary debate of randomized Phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J. Clin. Oncol. 19(Suppl. 18), 17S-20S (2001).
31. Sternberg CN, Parmar MKB. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J. Clin. Oncol. 19(Suppl. 18), 21S-26S (2001).
32. EORTC Genito-Urinary Group, Australia Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized trial. Lancet 354, 533-540 (1999).
33. Hall RR. Updated results of randomized controlled trials of neoadjuvant cisplatin (C), methotrexate (M), and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc. Am. Soc. Clin. Oncol. 21, 178a (2002) (Abstract 710).
34. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927-1934 (2003).
35. Sharif A, Holmberg M, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur. Urol. 45, 297-303 (2004).
36. Logothetis CJ, Johnson DE, Chong C et al. Adjuvant chemotherapy of bladder cancer: a preliminary report. J. Urol. 139, 1207-1211 (1988).
37. Skinner DG, Daniels JR, Russell CA et al The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145(3), 459-464 (1991).
38. Stöckle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 148, 302-307 (1992).
39. Stöckle M, Wellek S, Meyenburg W et al Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48, 868-875 (1996).
40. Freiha F, Reese J, Torti F. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine, and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155, 495-500 (1996).
41. Chester JD, Hall GD, Forster M, Protheroe AS. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions. Cancer Treat. Rev. 30, 343-358 (2004).
42. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann. Oncol. 11, 851-856 (2000).
43. Dimopoulis MA, Moulopoulas LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J. Clin. Oncol. 16, 1601-1612 (1998).
44. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19(20), 4005-4013 (2001)
45. Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a co-operative group report. J. Clin. Oncol. 22(14), 2781-2789 (2004).
46. Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol. 171, 1830-1834 (2004).
47. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin D. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167, 1295-1298 (2002)
48. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J. Urol. 169, 943-945 (2003).
49. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer. Pharmacoeconomics 21 (18), 1315-1330 (2003).
50. Lehmann J, Retz M, Stöckle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit. Rev. Oncol. Hematol. 47, 171-179 (2003).
51. von der Maase H, Hansen SW, Roberts JT et al, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 17(17), 3068-3077 (2000).
52. Sacristan JA, Kennedy-Martin T, Rosell R et al. Economic evaluation in a randomized Phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer 28, 97-107 (2000).
53. Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 97(Suppl. 8), 2064-2075 (2003).
54. del Muro XG, Condom E, Vigues F et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100, 1859-1867 (2004).
55. de Wit R. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97(Suppl. 8), 2120-2126 (2003).
56. Crawford ED, Wood DP, Petrylak DP, Scott J, Coltman CA, Raghavan D. Southwest Oncology Group studies in bladder cancer. Cancer 97(Suppl. 8), 2099-2108 (2003).
57. Raghavan D. Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol. Oncol. 21, 468-474 (2003).
58. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr. Opin. Oncol. 16, 257-262 (2004).
59. Small E, Halabi S, Dalbagni G et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 97(Suppl. 8), 2090-2098 (2003).
60. Bellmunt J, de Wit R, Abiol S, Tabernero J, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Crit. Rev. Oncol. Hematol. 47, 195-206 (2003).
61. Dinney CP, McConkey DJ, Millikan RE et al. Focus on bladder cancer. Cancer Cell 6(2), 111-116 (2004).
62. Kamat AM. Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care? Am. J. Clin. Onc. Rev. 2, 624-637 (2003).